We conducted a randomized, placebo-controlled, double-blind crossover trial using an n-of-1 approach that involved 20 patients with type 2 diabetes to assess individual responses to the SGLT2 inhibitor dapagliflozin. Here, SLC5A2 is linked to type 2 diabetes mellitus.